Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Hengrui Launches Antifungal in China for Vulvovaginal Candidiasis

publication date: Feb 9, 2024

Jiangsu Hengrui Pharma announced a China launch for Vivjoa® (oteseconazole) in China, a novel oral azole antifungal approved to treat severe vulvovaginal candidiasis (VVC). In a China Phase III trial, the 2-day oral regimen of Vivjoa showed superior efficacy to the previous standard-of-care, fluconazole, in women presenting with severe VVC. Oteseconazole selectively inhibits fungal CYP51, which is required for fungal cell wall integrity. Because of its chemical structure, oteseconazole has a lower affinity for human CYP enzymes than fungal CYP enzymes. In 2019, Hengrui acquired China rights to Vivjoa from Mycovia Pharma of North Carolina. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital